Â鶹´«Ã½É«ÇéƬ

Bumpus advances at FDA

Namandjé Bumpus has been named the principal deputy commissioner at the U.S. Food and Drug Administration. In this new leadership role with the FDA, she will work with a team to develop, advance and implement key public health initiatives and oversee the agency’s day-to-day operations.

Namandjé Bumpus

was previously the FDA’s chief scientist. In this role, she managed the research foundation, science and innovation that provides vital support for the agency’s public health mission. Before moving to the FDA, she ran a lab at Johns Hopkins University studying how P450 enzymes process antiretroviral drugs, which are used to treat human immunodeficiency virus, and antivirals used against hepatitis C.

Among her previous leadership roles, Bumpus served as associate dean for basic research and director of the pharmacology department at Hopkins and chair of a National Institutes of Health study section on xenobiotic and nutrient disposition and action. She has been president, treasurer, secretary and councilor of the American Society for Pharmacology and Experimental Therapeutics.

Bumpus’ awards and honors include the Leon I. Goldberg Award from the American Society for Clinical Pharmacology and Therapeutics, the James Gillette Award from the International Society for the Study of Xenobiotics, the John J. Abel Award in Pharmacology from the American Society for Pharmacology and Experimental Therapeutics and the Presidential Early Career Award for Scientists and Engineers. She is a fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine.

Küster and Riley win HUPO awards

Bernhard Küster

Nicholas Riley

Two Â鶹´«Ã½É«ÇéƬ and Â鶹´«Ã½É«ÇéƬ Biology members have been honored by the Human Proteome Organization. Bernhard Küster won the Distinguished Achievement in Proteomic Sciences Award for his ongoing contributions to the field of chemical proteomics. Nicholas Riley won the HUPO Rising Star Award, which recognizes early career researchers who have had an exceptional impact on the proteomics field and community.

Küster is a professor of proteomics and bioanalytics at the Technical University of Munich. His focuses on the biochemical actions of therapeutic drugs, the molecular mechanisms that play a role in cancer and how information about these two aspects can be used for individual approaches to clinical treatment. Recently, his lab published a novel quantitative proteomic approach for decrypting drug actions and protein modifications by dose- and time-resolved proteomics.

Küster is a deputy editor of the journal Â鶹´«Ã½É«ÇéƬ & Cellular Proteomics. His past honors including the HUPO Discovery in Proteomic Sciences Award and the Mattauch-Herzog Award from the German Mass Spectrometry Society. The TUM Institute for Advanced Study named him the Carl von Linde Senior Fellow in 2018, and he was elected to the German National Academy of Science in 2019.

Riley is an assistant professor of chemistry at the University of Washington. The investigates glycosylation patterns that govern health and disease using mass spectrometry-centric glycoproteomics and chemical glycobiology. His group is particularly interested in understanding how altered cell surface glycosylation phenotypes manifest in cancer progression and drive metastasis.

The Journal of Proteome Research recently named Riley a Rising Star in Proteomics and Metabolomics, and the American Society for Mass Spectrometry recognized him as an Emerging Talent in Academia.